Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi

“We got to present the subgroup analysis of the Transcend-NHL-001 mantle cell lymphoma cohort study. This is a study that investigated lisocabtagene maraleucel in patients with relapsed refractory mantle cell lymphoma. And this is actually a post hoc analysis of patients based on number of prior lines of therapy, as well as by response to prior Bruton tyrosine kinase inhibitor.”

Lisocabtagene maraleucel (liso-cel) has demonstrated its ability to yield durable complete responses in patients with heavily pretreated mantle cell lymphoma and was FDA-approved for this indication in May 2024.¹ Subgroup analyses of outcomes after liso-cel in these patients according to prior lines of therapy and prior Bruton tyrosine kinase inhibitor treatment were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois.²

CGTLive spoke with study coauthor Manali Kamdar, MD, to learn more about the subanalyses and its goal. She went over the different stratified groups, their treatment history, and disease characteristics.

REFERENCES

1. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. News release. FDA. May 30, 2024. Accessed May 30, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma
2. Palomba ML, Siddiqi T, Gordon LI, et al. Lisocabtagenemaraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL). Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7016